Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

Coronary Artery Disease Clinical Trial

Official title:

A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01863225
• Other study ID #: RVX222-CS-009
• Status: Terminated
• Phase: Phase 2
• First received: May 16, 2013
• Last updated: May 8, 2015
• Start date: May 2013
• Est. completion date: June 2013

Study information

• Verified date: May 2015
• Source: Resverlogix Corp
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

This study is designed to characterize the pharmacokinetics of multi-dose RVX000222 and atorvastatin and rosuvastatin when either statin is administered in combination with RVX000222 in subjects with dyslipidemia.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male and female patients = 18 to = 65 years of age with or without documented coronary artery disease.

• Taking statin therapy for at least 30 days prior to Screening (Visit 1).

• In the opinion of the investigator, patient currently on statin therapy other than atorvastatin 40 mg or rosuvastatin 20 mg or atorvastatin 80 mg or rosuvastatin 40 mg who could be switched to one of these regimens at Visit 1 for the duration of the study.

Exclusion Criteria:

• Clinically significant heart disease which will require coronary bypass, PCI, cardiac transplantation, surgical repair and/or replacement during the course of the study.

• Coronary artery bypass graft (CABG) procedure within the past 90 days.

• Have a body mass index (BMI) greater than 36 kg/m2.

• Patients of East Asian descent (due to pharmacological food effect noted for rosuvastatin).

• Previous or current diagnosis of severe heart failure (NYHA Class III-IV) or a documented left ventricular ejection fraction (LVEF) of < 25% as determined by contrast left ventriculography, radionuclide ventriculography or echocardiography. The absence of an LVEF measurement in a patient without a previous or current diagnosis of heart failure does not prohibit entry into the study.

• Patients with evidence of cardiac electrophysiologic instability including a history of uncontrolled ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias with a ventricular response heart rate of > 100 beats per minute at rest within 4 weeks prior to Visit 1.

• Evidence of renal impairment

• Have hypertension that is uncontrolled defined as 2 consecutive measurements of sitting blood pressure of systolic >160 mmHg or diastolic > 95 mmHg at Visit 1.

• Women of child-bearing potential who do not agree to use two reliable methods of birth control during the study and for one month following the last dose of study drug, or pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive ß-hCG laboratory test (= 5 IU/L) at the time of enrollment. Where women of child-bearing potential are defined as women not surgically sterilized and between menarche and 1 year post menopause, and a reliable method of birth control includes use of oral contraceptives or levonorgestrel; or a reliable barrier method of birth control (diaphragms; cervical caps; condoms; intrauterine devices; partner with vasectomy; or abstinence).

• Current or recent (within 12 month prior to Visit 1) treatment with immunosuppressants (e.g., Cyclosporine).

• Triglycerides > 4.5 mmol/L at screening Visit 1.

• Use of fibrates of any dose or niacin/nicotinic acid 250 mg or more within 90 days prior to Visit 1

• Any medical or surgical condition which might significantly alter the absorption, distribution, metabolism or excretion of medication including, but not limited to any of the following: cholecystitis, Crohn's disease, ulcerative colitis, or any gastric bypass alteration.

• Evidence of hepatic disease

• A total bilirubin that is > ULN by local laboratory at screening, Visit 1

• History of malignancy of any organ system, treated or untreated, within the past 5 years of Visit 1 whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.

• History or evidence of drug or alcohol abuse within 12 months of Visit 1.

• Current dependence on nicotine containing products.

• Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.

• Use of any HIV and/or chemotherapy drugs, and/or antibiotics within 30 days or 5 half-lives of Visit 2, whichever is longer.

• Use of other investigational drugs and devices at the time of enrollment, or within 30 days or 5 half-lives of Visit 2, whichever is longer.

• History of noncompliance to medical regimens or unwillingness to comply with the study protocol.

• Any condition that in the opinion of the investigator would confound the evaluation and interpretation of efficacy and/or safety data.

• Persons directly involved in the execution of this protocol.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Dyslipidemia
• Dyslipidemias
• Myocardial Ischemia

Intervention

Drug:
• RVX000222
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
• Rosuvastatin
20 mg daily, 28-42 days
• Atorvastatin
40 mg daily, 28-42 days
• Rosuvastatin
40 mg daily, 28-42 days
• Atorvastatin
80 mg daily, 28-42 days

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital / CMAX	Adelaide	South Australia

Sponsors (2)

Lead Sponsor	Collaborator
Resverlogix Corp	South Australian Health and Medical Research Institute

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterization of the pharmacokinetics of RVX000222 capsule formulation in combination with either atorvastatin or rosuvastatin in patients with dyslipidemia.	The plasma concentration-time profile of RVX000222 capsule formulation and its metabolites on Days 1 and 14 of 200 mg daily RVX000222 in combination with either atorvastatin or rosuvastatin, including pharmacokinetic parameters Cmax, Tmax, Cmin, AUC0-12, AUC12-24, AUC0 24, and metabolite ratio.	14 days	No
Secondary	Characterization of the pharmacokinetics of atorvastatin and rosuvastatin when either is administered in combination with RVX000222 capsule formulation to patients with dyslipidemia.	The plasma concentration-time profile of either atorvastatin and metabolites or rosuvastatin and metabolites on Days -1 and 14 of 200 mg daily RVX000222 in combination with the statin, including pharmacokinetic parameters Cmax, Tmax, Cmin, AUC0-12, AUC12-24, AUC0 24, and metabolite ratio.	14 days	No
Secondary	Evaluation of safety and tolerability of RVX000222 capsule formulation administered in combination with stable doses of either atorvastatin or rosuvastatin in patients with dyslipidemia.	Adverse events, serious adverse events, vital signs, clinical chemistry and haematological variables will be collected and summarized across treatment groups.	14	Yes